within Pharmacolibrary.Drugs.ATC.L;

model L01XK04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.55,
    Cl             = 0.00011166666666666667,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.42,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0033333333333333335,
    Tlag           = 15.0,            
    Vdp             = 0.781,
    k12             = 40.5,
    k21             = 40.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XK04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Talazoparib is an orally administered poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. It is currently approved for medical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with cancer following oral administration.</p><h4>References</h4><ol><li><p>Yu, Y, Durairaj, C, Shi, H, &amp; Wang, DD (2020). Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer. <i>Journal of clinical pharmacology</i> 60(2) 218–228. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1520&quot;>10.1002/jcph.1520</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31489639/&quot;>https://pubmed.ncbi.nlm.nih.gov/31489639</a></p></li><li><p>Talebi, Z, Garrison, DA, Eisenmann, ED, Parmar, K, Shapiro, GI, Rudek, MA, Sparreboom, A, &amp; Jin, Y (2023). Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method. <i>Heliyon</i> 9(11) e20972–None. DOI:<a href=&quot;https://doi.org/10.1016/j.heliyon.2023.e20972&quot;>10.1016/j.heliyon.2023.e20972</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37908705/&quot;>https://pubmed.ncbi.nlm.nih.gov/37908705</a></p></li><li><p>Luo, Y, Cheng, Y, Wu, C, Ye, H, Chen, N, Zhang, F, Wei, H, &amp; Xu, B (2023). Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors. <i>Investigational new drugs</i> 41(3) 503–511. DOI:<a href=&quot;https://doi.org/10.1007/s10637-023-01351-w&quot;>10.1007/s10637-023-01351-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37171721/&quot;>https://pubmed.ncbi.nlm.nih.gov/37171721</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XK04;
